159 related articles for article (PubMed ID: 20658564)
1. Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women.
Cummings SR; McClung M; Reginster JY; Cox D; Mitlak B; Stock J; Amewou-Atisso M; Powles T; Miller P; Zanchetta J; Christiansen C
J Bone Miner Res; 2011 Feb; 26(2):397-404. PubMed ID: 20658564
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene.
Powles TJ; Diem SJ; Fabian CJ; Neven P; Wickerham DL; Cox DA; Muram D; Agnusdei D; Dowsett SA; Amewou-Atisso M; Cummings SR
Breast Cancer Res Treat; 2012 Jul; 134(1):299-306. PubMed ID: 22484799
[TBL] [Abstract][Full Text] [Related]
3. Gynecologic effects of arzoxifene in postmenopausal women with osteoporosis or low bone mass.
Goldstein SR; Bhattoa HP; Neven P; Cox DA; Dowsett SA; Alam J; Sipos A; Muram D
Menopause; 2012 Jan; 19(1):41-7. PubMed ID: 21993078
[TBL] [Abstract][Full Text] [Related]
4. Effects of arzoxifene on bone mineral density and endometrium in postmenopausal women with normal or low bone mass.
Bolognese M; Krege JH; Utian WH; Feldman R; Broy S; Meats DL; Alam J; Lakshmanan M; Omizo M
J Clin Endocrinol Metab; 2009 Jul; 94(7):2284-9. PubMed ID: 19351734
[TBL] [Abstract][Full Text] [Related]
5. Effects of arzoxifene on bone, lipid markers, and safety parameters in postmenopausal women with low bone mass.
Downs RW; Moffett AM; Ghosh A; Cox DA; Dowsett SA; Harper K
Osteoporos Int; 2010 Jul; 21(7):1215-26. PubMed ID: 19798460
[TBL] [Abstract][Full Text] [Related]
6. Incidence of vertebral fractures in calcium and vitamin D-supplemented postmenopausal Brazilian women with osteopenia or osteoporosis: data from Arzoxifene Generations Trial.
Arantes HP; Gimeno SG; Chiang AY; Bilezikian JP; Lazaretti-Castro M
Arch Endocrinol Metab; 2016 Feb; 60(1):54-9. PubMed ID: 26909483
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial.
Silverman SL; Christiansen C; Genant HK; Vukicevic S; Zanchetta JR; de Villiers TJ; Constantine GD; Chines AA
J Bone Miner Res; 2008 Dec; 23(12):1923-34. PubMed ID: 18665787
[TBL] [Abstract][Full Text] [Related]
8. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
[TBL] [Abstract][Full Text] [Related]
9. Prevention of breast cancer by newer SERMs in the future.
Powles T
Recent Results Cancer Res; 2011; 188():141-5. PubMed ID: 21253796
[TBL] [Abstract][Full Text] [Related]
10. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.
Siris ES; Harris ST; Eastell R; Zanchetta JR; Goemaere S; Diez-Perez A; Stock JL; Song J; Qu Y; Kulkarni PM; Siddhanti SR; Wong M; Cummings SR;
J Bone Miner Res; 2005 Sep; 20(9):1514-24. PubMed ID: 16059623
[TBL] [Abstract][Full Text] [Related]
11. How to manage postmenopausal osteoporosis?
Body JJ
Acta Clin Belg; 2011; 66(6):443-7. PubMed ID: 22338309
[TBL] [Abstract][Full Text] [Related]
12. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial.
Reginster JY; Felsenberg D; Boonen S; Diez-Perez A; Rizzoli R; Brandi ML; Spector TD; Brixen K; Goemaere S; Cormier C; Balogh A; Delmas PD; Meunier PJ
Arthritis Rheum; 2008 Jun; 58(6):1687-95. PubMed ID: 18512789
[TBL] [Abstract][Full Text] [Related]
13. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
Chesnut CH; Skag A; Christiansen C; Recker R; Stakkestad JA; Hoiseth A; Felsenberg D; Huss H; Gilbride J; Schimmer RC; Delmas PD;
J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
[TBL] [Abstract][Full Text] [Related]
14. Management of postmenopausal osteoporosis and the prevention of fractures.
Gambacciani M; Levancini M
Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator.
Fabian CJ; Kimler BF; Anderson J; Tawfik OW; Mayo MS; Burak WE; O'Shaughnessy JA; Albain KS; Hyams DM; Budd GT; Ganz PA; Sauter ER; Beenken SW; Grizzle WE; Fruehauf JP; Arneson DW; Bacus JW; Lagios MD; Johnson KA; Browne D
Clin Cancer Res; 2004 Aug; 10(16):5403-17. PubMed ID: 15328178
[TBL] [Abstract][Full Text] [Related]
16. Prevention and treatment of osteoporosis in women with breast cancer.
Mincey BA; Moraghan TJ; Perez EA
Mayo Clin Proc; 2000 Aug; 75(8):821-9. PubMed ID: 10943237
[TBL] [Abstract][Full Text] [Related]
17. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis.
Cranney A; Adachi JD
Drug Saf; 2005; 28(8):721-30. PubMed ID: 16048357
[TBL] [Abstract][Full Text] [Related]
18. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
Lee WL; Chao HT; Cheng MH; Wang PH
Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
[TBL] [Abstract][Full Text] [Related]
19. Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis.
Lewiecki EM
J Womens Health (Larchmt); 2009 Oct; 18(10):1615-26. PubMed ID: 19857095
[TBL] [Abstract][Full Text] [Related]
20. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]